Day: December 15, 2025

Abivax Presents Third Quarter 2025 Financial ResultsCash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial information for the nine months ended September 30, 2025. The unaudited interim condensed consolidated financial statements as of and for the three and nine months ending September 30, 2025, reviewed by the Company’s Board of Directors on December 11, 2025, have been reviewed by the Company’s external auditors. Abivax...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION. This announcement is not a prospectus and does not constitute an offer to sell or the solicitation of an offer to purchase the securities described herein, nor shall there be any sale of the securities referred to herein in or into any jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Neither this communication nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction....

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Value Line, Inc., (NASDAQ: VALU) reported financial results for the first half of its fiscal year, ended October 31, 2025.During the six months ended October 31, 2025, the Company’s net income of $12,142,000, or $1.29 per share, was 4.9% above net income of $11,572,000, or $1.23 per share, for the six months ended October 31, 2024.   The Company’s revenues of $10,275,000 from Eulav Asset Management (EAM) increased $1,404,000 or 15.8% above the prior fiscal year.   During the six months ended October 31, 2025, the Company’s total investment gains of $3,201,000 was 10.6% above total investment gains in the prior fiscal year.   Retained earnings at October 31, 2025, were $119,426,000, an increase of 5.3% compared to retained earnings at April 30, 2025.   Shareholders’ equity reached $105,489,000...